Soleno is developing a once-daily oral tablet, diazoxide choline, in Phase III clinical trials for the treatment of Prader-Willi Syndrome. No therapies are approved to treat this rare genetic condition, which causes chronic insatiable hunger as well as behavioural problems, cognitive disabilities, low muscle tone and short stature. The product has orphan drug designation in the US and Europe. Soleno is a VIPE (Venture Investment in Public Equity) and is listed on Nasdaq with the ticker SLNO.
Location: United States, California, Redwood City
Employees: 11-50
Total raised: $89M
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | Abingworth... | abingworth... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 29.03.2022 | - | $15M | - |
| 26.06.2020 | - | $57.5M | - |
| 20.12.2018 | - | $16.5M | Abingworth... |
Mentions in press and media 10
| Date | Title | Description |
| 03.05.2024 | Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock | REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, annou... |
| 02.05.2024 | Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock | - |
| 08.03.2024 | Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as r... |
| 08.03.2024 | Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 06.03.2024 | Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results | - |
| 19.12.2022 | Soleno Therapeutics Announces Financing Commitment for up to $60 Million | - |
| 01.04.2022 | Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering | REDWOOD CITY, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the clo... |
| 29.03.2022 | Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering | REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pri... |
| 29.03.2022 | Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering | - |
| 26.06.2020 | Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares | - |